Phase I studies of nogitecan hydrochloride for Japanese

International Journal of Clinical Oncology

Volumn 7, Issue 3, 2002, Pages 177-186

  Kobayashi, Kunihiko ^a   Hino, Mitsunori ^b   Fukuoka, Masahiro ^c   Takeuchi, Kunio ^d   Furuse, Kiyoyuki ^e   Yoneda, Shuichi ^a   Hasegawa, Koichi ^f   Noda, Kiichiro ^g   Kinoshita, Hiroaki ^h   Kimura, Ikuro ⁱ   Taguchi, Tetsuo ^j   Kanamaru, Ryunosuke ^k   Horikoshi, Noboru ^l   Niitani, Hisanobu ^m  

^a SAITAMA CANCER CENTER   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Hyogo Prefecture Health Promotion Association   (Japan)

^e Osaka Central Hospital   (Japan)

^f Tsuboi Hospital   (Japan)

^g KINKI UNIVERSITY   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^j Japan Soc for Cancer Chemotherapy   (Japan)

^k TOHOKU UNIVERSITY   (Japan)

^l CANCER INSTITUTE HOSPITAL   (Japan)

^m Tokyo Society for Research of Cancer Chemotherapy   (Japan)

more..

Author keywords

Phase I study; Topoisomerase I inhibitor; Topotecan

Indexed keywords

CAMPTOTHECIN DERIVATIVE; TOPOTECAN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; ENZYME INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; JAPAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; BLOOD CELL COUNT; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; GASTROINTESTINAL DISEASE; HALF LIFE TIME; HEMATOLOGIC DISEASE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GASTROINTESTINAL DISEASES; HALF-LIFE; HEMATOLOGIC DISEASES; HUMAN; JAPAN; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; TOPOTECAN; HUMANS; MIDDLE AGED;

EID: 0035985935     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200026     Document Type: Article

References (22)

1. Plant antitumor agents 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
3. Camptothecin induces protein-linked DNA breaks via DNA topoisomerase I
4. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
5. Treatment of malignant melanoma with camptothecin (NSC-100880)
6. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
7. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity
8. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
9. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
10. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy
11. Evaluation of 9-dimethyl-aminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
12. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
13. A phase I study of weekly administration of CPT-11 in lung cancer
14. Phase I clinical study of CPT-11
15. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks
16. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38
17. Pharmacokinetic profile of irinotecan hydrochloride (CPT-11)
18. pH dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
19. An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as five daily infusions every 21 days to women with advanced epithelial ovarian carcinoma
20. Phase II study of topotecan in extensive stage small cell lung cancer
21. Phase II study of topotecan in advanced head and neck cancer: Identification of anactive new agent